Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Background Preclinical evidence suggests that cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors enhance antitumor immunity. We conducted a phase I trial of ribociclib (CDK4/6 inhibitor) plus spartalizumab (PD-1 inhibitor) in patients with hormone receptor (HR)-positive/HER2-negative metastatic br...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Sara M Tolaney, Tianyu Li, Elizabeth A Mittendorf, Geoffrey I Shapiro, Stephanie K Dougan, Nabihah Tayob, Joyce F Liu, Khanh Do, Heather Parsons, Molly DiLullo, Eileen Wrabel, Lestat R Ali, Ana C Garrido-Castro, Noah Graham, Christina Herold, Jennifer Desrosiers, Shom Goel, Amy J Williams
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2025-02-01
Serija:	Journal for ImmunoTherapy of Cancer
Online dostop:	https://jitc.bmj.com/content/13/2/e010430.full
Oznake:	Označite Brez oznak, prvi označite!